Expression Variation: Its Relevance to Emergence of Chronic Disease and to Therapy by Mayburd, Anatoly L.
Expression Variation: Its Relevance to Emergence of
Chronic Disease and to Therapy
Anatoly L. Mayburd*
CPA Global, Alexandria, Virginia, United States of America
Abstract
Background: Stochastic fluctuations in the protein turnover underlie the random emergence of neural precursor cells from
initially homogenous cell population. If stochastic alteration of the levels in signal transduction networks is sufficient to
spontaneously alter a phenotype, can it cause a sporadic chronic disease as well – including cancer?
Methods: Expression in .80 disease-free tissue environments was measured using Affymetrix microarray platform
comprising 54675 probe-sets. Steps were taken to suppress the technical noise inherent to microarray experiment. Next, the
integrated expression and expression variability data were aligned with the mechanistic data covering major human chronic
diseases.
Results: Measured as class average, variability of expression of disease associated genes measured in health was higher than
variability of random genes for all chronic pathologies. Anti-cancer FDA approved targets were displaying much higher
variability as a class compared to random genes. Same held for magnitude of gene expression. The genes known to
participate in multiple chronic disorders demonstrated the highest variability. Disease-related gene categories displayed on
average more intricate regulation of biological function vs random reference, were enriched in adaptive and transient
functions as well as positive feedback relationships.
Conclusions: A possible causative link can be suggested between normal (healthy) state gene expression variation and
inception of major human pathologies, including cancer. Study of variability profiles may lead to novel diagnostic methods,
therapies and better drug target prioritization. The results of the study suggest the need to advance personalized therapy
development.
Citation: Mayburd AL (2009) Expression Variation: Its Relevance to Emergence of Chronic Disease and to Therapy. PLoS ONE 4(6): e5921. doi:10.1371/
journal.pone.0005921
Editor: Raya Khanin, University of Glasgow, United Kingdom
Received November 20, 2008; Accepted May 13, 2009; Published June 15, 2009
Copyright:  2009 Mayburd. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: CPA Global commited USD 300. The author can deposit $300 immediately. The funders had no role in study design, data collection and analysis,
decision to publish or preparation of the manuscript.
Competing Interests: The author has declared that no competing interests exist.
* E-mail: AMayburd@cpaglobal.com
Introduction
The studies of gene expression variability started relatively
lately, with the advent of high-throughput technologies of analysis
[1,2]. These studies revealed a striking and fundamental fact that
despite identical genotypes, individuals within the same species at
the same conditions express gene products at very different levels.
These quantitative differences span a range of several orders of
magnitude [3]. In a recent large scale study both extrinsic and
intrinsic character of such variations was shown [4]. Since
‘‘health’’ status can be defined as homeostatic balance, the ability
of fluctuations to propagate along regulatory chain is related to the
ability to induce dramatically different cellular states based on bi-
state/bi-stability model [5]. The effect of expression stochasticity
upon spontaneous differentiation of progenitor cells was studied in
[6]. According to the publication, stochastic fluctuations in the
turnover of two proteins, Notch and Delta, might underlie the
random emergence of neural precursor cells from initially
homogenous cell population. If stochastic alteration of the levels
in signal transduction networks is sufficient to spontaneously alter
a phenotype, can it cause a sporadic chronic disease as well?
A study was published comparing non-disease and disease
state, detecting de-regulation, as a signature of disease mecha-
nism [7]. Another study points to the link between excessive
expression of non-mutated protein in chromosomal trisomy and
the risk of Alzheimer’s disease development in the age of fifties for
the affected individuals [8]. The publication proceeds to
extrapolate this observation to the general causes of neurode-
generative disease. The review [8] also discusses the impact of
non-mutated gene expression upon the probability of sporadic
prion disease, taupathies, Parkinson and Alzheimer’s disease.
Many earlier publications also present the connection between
anomalous gene dosage and development of neurodegenerative
disease [9]. Such situation qualitatively differs from variations of
gene expression at normal gene dosage, making the work [8]
especially important, since it appears to produce such an
interpretation of variation vs. disease. The publications [10–13]
consider stochastic origin of diseases including tumors in the
condition of haploinsufficiency. In such cases a single gene copy
does not produce enough of a transcription factor (tumor
suppressor) to always ensure a concentration above the critical
[10–12]. Since the function of stochastically modulated signal
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exceedingly leveraged [13].
While providing a link between expression variability and
disease, the prior publications appear to be confined to particular
diseases (neurodegenerative, particular tumors) and certain genes,
thus they do not provide a global view of the possible connection
between normal gene expression variance and mechanism of
subsequent sporadic disease emergence. By contrast, this work
presents a genomic scale study into all major chronic diseases,
including aging and such a scope may be of interest.
Results
Elevated expression variability associates with disease
Figure 1 presents normalized levels of expression, consistency of
differential expression and integrated panel variability for 54675
probe-sets comprising the high density U133 Plus 2.0 microarray
platform by Affymetrix. For cancer-related genes (,2900 probe-
sets) variability is higher in norm as compared to random genes.
The same refers to differential expression and expression. For
prospective anti-cancer targets, the expression parameters corre-
late with the extent of clinical development, being higher for FDA
approved targets (black bars) as compared with the mix of target
and non-targets (striped bars, ‘‘cancer-related’’ category).
Since variability was measured in normal state, its link to the
propensity of a gene to become a successful target is significant.
Typically, participation in the essential mechanism of pathogenesis
establishes a gene as a target. On the other hand, the elevated
expression variation was measured prior to development of a
disease – hence it may be causative to the subsequent
pathogenesis. A concern exists that the extent of clinical
development may not objectively reflect the extent of mechanistic
participation of a gene but may be distorted by other factors, such
as market niche, the historical duration of study, dominant
opinions in the field etc. To ensure that the extent of variability
indeed parallels the objective extent of mechanistic participation,
the variability data were aligned with differential expression
consistency and metric of tissue-specific expression. Prior works
show that differential expression consistency is an objective metric
providing significant enrichment in the FDA-approved and
proposed anti-cancer targets [21]. Such a link provides indirect
measure of relevance to the disease mechanism. The criterion of
tissue-specific expression is another routine computational filter
[22] in target selection and is independent vs. non-mechanistic
(marketing) factors. Ideally, it seeks the target candidates over-
expressed only in a particular lineage and absent in all the rest.
Thus both systemic and the lineage-related side-effects are
minimized.
Figure 2 illustrates a link between consistency of differential
expression in transition from norm to cancer and expression
variability in the norm. According to the Figure 2, the increased
tendency to be differentially expressed in cancer is directly
proportional to variability in normal state.
Figure 3 compares random genes and the populations of
prospective and approved anti-cancer targets selected by the
criteria of tissue-specific expression, see Methods and more
detailed presentation in Supporting materials (Text S1, pages
29–46). In the group of ,190 probe-sets simultaneously top
ranked by MAXc/AV, MAXc/MAXN, MAXc/VULNER-
ABLES the level of variability in the norm was by far the highest.
At the same time, this group of genes was strongly enriched in
FDA-approved targets and proposed target candidates, such as
MAGE (A3, A6, A2, A11), MS4A1, REG4, MSLN, IL1A,
ENPEP, TYR, RARA, FCLRA. The data by Figure 2 and 3
provide an additional link between anti-cancer target enrichment
Figure 1. Expression parameters of random genes vs the
parameters of therapeutic anti-cancer targets. Presented is a
comparison of expression parameters for random genes (grey bars),
cancer-related genes, both target and non-target (striped bars),
proposed and developing anti-cancer targets (checkered bars) and
successful anti-cancer targets (black bars). The parameters of expression
were estimated as described in the Methods. The differential expression
refers to the comparison between norm and cancer. The confidence
intervals were computed with the significance level a=0.05
doi:10.1371/journal.pone.0005921.g001
Figure 2. Differential expression as an alternative criterion of
mechanistic involvement vs expression variation. Differential
expression consistency in norm vs cancer transition was aligned with
variability levels. Total population of random and disease-associated
genes was included in the analysis.
doi:10.1371/journal.pone.0005921.g002
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role.
To ensure that these observations are not specific for cancer
alone, similar analysis was conducted for other classes of disease-
related genes, see Figure 4. Mining the database ‘‘Genes’’ at NCBI
with keywords corresponding to particular disorders produced
gene aliases associated with these disorders based on the analysis of
scientific and medical literature. The expression variability trend
first discovered for anti-cancer targets vs random genes was
confirmed for all major chronic conditions.
Figure 5 addresses a baffling phenomenon of a gene’s multiple
participation in several chronic conditions, most notably the
similarity between the set of genes active in neurodegenerative
disease and cancer [16]. Other multiple participation parallels
were observed, such as between obesity and depression [17,18].
While the latter link can be also explained by behavioral and
psychological changes, an alternative explanation calls for a
common signal pathway involvement [19,20]. The lists of gene
aliases (extracted as described in Methods) were aligned and the
Index of Multiple Participation was computed. According to the
data, each gene participated in ,2 chronic disorders on average
and thus our findings support the prior isolated observations that
genes active in the mechanism of a single disorder may be a part of
multiple disease mechanisms [16–20]. The expression parameters
of such multiple participants were plotted in Figure 5.A. The
degree of gene expression in norm (EN) and cancer (EC) was
increasing for disease participants vs. random genes. Even more
prominent trend was observed for differential expression consis-
tency (DEXCON) and variability (VAR) that were steadily
increasing in proportion to the Index of Multiple participation,
being maximal for multiple participants.
Figure 5.B presents the results of querying of a patent database
with Boolean keyword strings, comprising a combination of a gene
list and terms describing disease association (P3.2). Under
comparable conditions, the gene list selected from the highest
variability category produced 4–8 fold greater number of hits as
compared to the gene list of the same size selected from the least
variable category. Figure 5.B points to a strong correlation existing
between the level of expression variability and the extent of disease
association.
Validation of results
A possibility exists that the differences between random control
and disease-associated genes are not objective, but arise acciden-
tally due to a particular composition of the integrated panel. To
rule this possibility out, multiple (8) sub-panel compositions were
generated by random bootstrapping and in each composition
random genes were compared with therapeutic target genes (P3.3).
The difference between the groups under comparison exceeds the
relevant confidence intervals.
A hypothesis was advanced that the elevated variability in
disease-related categories may be a function of higher expression
also observed in these categories. To test this possibility, variability
as a function of copy-number was plotted (Figure 6.A) using
multiple brackets of copy number values (in arbitrary units). The
observed relationship pointed to higher variation at lower copy-
numbers, running counter to the above mentioned hypothesis.
Still another possibility of an artifact resides in the fact that a
very sensitive measure was employed as a variation criterion. A
propagated error, associated with a ratio of outliers can be very
significant and an additional test is needed to evaluate its
neutralization by aggregation of multiple datasets in a panel.
Coefficient of Variation (CV) was chosen as a less sensitive, but
more reliable alternative metric, taking into account the scattering
behavior of the entire population of N values in a project.
Figure 6.B presents comparative variability for random genes and
disease-associated categories.
The Figure 6.B indicates that the trend, observed using MAX/
MIN is preserved while using CV (compare groups 1 and 3). High
confidence interval for the group 2 still allows confirmation of the
Figure 3. Comparative expression variation of random genes
and tissue-specific anti-cancer targets. The variability level in the
random gene class (grey bar) was compared with tissue-specific anti-
cancer target candidates and targets (striped bar). The latter sub-set
was formed by selecting genes expressed in a single tissue lineage and
over-expressed in cancer.
doi:10.1371/journal.pone.0005921.g003
Figure 4. Expression variability in chronic diseases. Averaged
panel variability of gene expression was measured for different chronic
disease states, including aging (250–500 probes-sets per a disease).
doi:10.1371/journal.pone.0005921.g004
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and especially measured by MAX/MIN is significantly greater in
cancer tissues, reflecting expression deregulation.
Quantitative ontological analysis
Per processing as discussed in Methods, total gene population
formed ,7500 functional categories, with 3900 of those having
non-zero population. Functional enrichments between the vari-
ability class and the total gene pool were computed (see folder P4
of Supporting online materials). The high variability class
displayed maximal enrichments for the genes controlling tissue
and organ development, proliferation, muscle contraction, che-
motaxis, ion channel functioning, neurotransmitter release and
processing, immune response. By contrast, low variability class
displayed enrichments for the genes controlling enzymatic
metabolic reactions, structural proteins, cell division, ribosome,
translation factors. The analysis of variability extremes was
followed by the study of individual diseases (Supporting materials,
section P4). The results indicate that the most-enriched functional
categories correspond to the currently accepted disease mecha-
nism. For example, tissue morphogenesis and proliferation
regulation was the dominant category for cancer, neurotransmis-
sion – for depression, etc. This result suggests that disease-
associated variability is concentrated among mechanistically
essential genes.
The FENR values were assembled in the panel, with two sub-
profiles in every populated functional category, one for random
negative control and another for the diseases being grouped
together. Such grouping allowed exploration of the features
generic to all chronic disorders using the rationale presented in
Methods. The functional categories ranked based on p-value of T-
test vs. random negative control were subjected to text-mining, as
well as the total list of categories. The results are given by Figure 7.
According to the plotting, top-ranking disease-related functional
categories respond to the keyword ‘‘regulation’’ twice as frequently
as the total population of categories and four fold more frequently
if compared with lowest-ranking categories (representing random
gene population). More surprising, however, was the finding that
positive regulation is much more prominent among top-ranking
disease-related categories as compared to the lowest ranking
categories or total list of categories. The total population of
categories appears to display approximate balance between
positive and negative regulation, according to our analysis. This
balance between positive and negative regulation appears to shift
in favor of positive regulation in the categories most associated
with disease and this observation suggests some fundamental
biological role.
Practical applications of the current project were explored
below. Figure 8.A compares the targets of FDA approved anti-
cancer drugs, proposed and developing anti-cancer targets, targets
of non-cancer disease therapies and random genes, plotted as a
ROC curve as a function of ranked variability score. The said
score is a combined variation metric, comprised of individual
features of MAX/MIN, CV, kurtosis and differential expression
consistency. In the context of Figures 1–4, it follows that anti-
cancer successful targets display higher variability than the
corresponding candidate genes and the magnitude of variability
may (to a point!) be a predictor of clinical success. In fact, the odds
Figure 5. Variation of gene’s expression correlates with the gene’s association with chronic disease. A. Relationship between
participation in multiple chronic conditions and parameters of expression. Striped bars – the genes participate in 0 chronic conditions, Checkered
bars – participation in 1 chronic conditions, grey bars – participate in 2–3 chronic conditions, black bars - participates in 4–7 chronic conditions. The
parameters of expression comprise EN – expression in norm; EC – expression in cancer, DEXC – differential expression consistency between norm vs.
cancer; VAR – variability of expression. B. In this computational experiment, three categories of gene expression were identified: highly-variable (black
bars), at average variation level (grey bars) and at minimal variation level (striped bars). The lists of genes of equal size (1000) were selected to be a
part of Boolean query of the structure: Group A: [(gene list) and ((biomarker* or (diagnostic adj marker*) or (prognostic adj marker*))]. Group B: [(gene
list) and (disease or disorder)]. Group C: [(gene list) and (longevity or mortality)]. Each gene list of differing variability was incorporated in the query of
a patent database (Micropatent by Thomson) and the numbers of hits were plotted for each group, designated as above.
doi:10.1371/journal.pone.0005921.g005
Disease Origin
PLoS ONE | www.plosone.org 4 June 2009 | Volume 4 | Issue 6 | e5921of high-variation vs. low variation gene to be a target of anti-
cancer drug or si-RNA approach differ ,15–20 fold on the
opposing edges of a ranked dataset. The odds ratio reaches 5 fold,
comparing average variability and high variability candidates.
The trend observed for non-cancer targets appears to be the
opposite: the candidate genes (Figure 4) appear to be somewhat
more variable than the finally approved targets (Figure 8.A), while
the latter are somewhat more variable than random genes.
Figure 8.B presents the result of the study of E.coli gene
expression (Supporting Online Materials Text S1, p. 23–24; folder
P6). Different features, exploring expression variation (same as in
Figure 8.A) were applied to random genes and pharmacological
targets. Increased proportion of un-annotated genes was observed
in high-variation subset.
On the contrary, the population of successful antibiotic targets
displayed decreased expression variation, while displaying in-
creased evolutional conservation (defined as an ability to be
expressed in a profile comprised of selected species, Figure 8.C).
Discussion
A. The link between expression variation and disease:
putative novel diagnostic tests
The main result of the current research is in the finding that
expression variability of disease-associated genes is higher than
that of random genes. Several possibilities of an artifact were
considered (see validation section of Results) and found to be
absent. Assuming validity of these findings, the above trend was
observed in healthy state and a causal link to inception of
pathology may be hypothesized (hypothesis 1). An alternative
(hypothesis 2) calls for elevated variability to be a hallmark of a
gene’s disease-relatedness, but no direct role in pathological
mechanism can be attributed.
The references 5, 6, 8, 10–12, 21 support the hypothesis 1,
pointing to a possibility of disease inception due to dramatic
positive or negative variation in expression of a single gene.
Indeed, decrease in a single gene expression level due to haplo-
insufficiency of tumor suppressors is carcinogenic. Conversely,
engineered over-expression of a signal protein triggers cancer in
normal skin [21]. Apparently, similar outcomes can follow
anomalous expression due to stochastic variation of gene
expression level. Such variations may arise at pre-natal stage.
Epigenetic factors and accompanying stochastic noise may exert
fateful influence at the stage of zygote. At this point only a few
transcript copies are available per a locus and the disproportionate
consequences of random fluctuations may define systemic
expression profile [5]. Considering rapid onset of differentiation
in zygote, this profile may get permanently imprinted, exerting an
impact on future health, disease and longevity status of an
individual [22]. By this or by a combination of conceivable
mechanisms, the resulting cellular population becomes very
heterogeneous in terms of systemic expression profiles [23].
According to the hypothesis 1, a fraction of each population is
essentially pre-pathological due to insufficient or excessive gene
expression. The selective evolutional pressure (and likely existence
of controlling processes) requires the fraction of this borderline
sub-population to be small at least toward the end of reproductive
age. However, the systemic resilience appears to decrease after a
certain point in age, as a consequence the weight of the mal-
functional cellular population and the severity of this malfunction
increases with age. Thus, the link between disease and expression
variability can be qualitatively explained. If such interpretation is
Figure 6. Validation of results. A. Expression variability measured as a function of transcript copy-number. The 54675 expression values measured
on a single microarray chip were normalized, with the average copy-number set to 1. The normalized values were split into brackets, expressed in the
arbitrary copy-number units. B. Comparison of different expression variability metrics. The groups 1 and 2 represent MAX/MIN; the groups 3 and 4
represent Coefficient of Variation (CVx50), brought to the comparable scale. The groups 1 and 3 belong to variations measured in normal tissues,
while the groups 2 and 4 refer to cancer tissues. The black bars stand for the targets of FDA approved anti-cancer drugs, the grey bars stand for the
developing and proposed anti-cancer targets, striped bars indicate random genes.
doi:10.1371/journal.pone.0005921.g006
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ments as diagnostic tests for disease predisposition.
Indeed, increased cell-to-cell variation of a given gene
expression would indicate loose regulatory control and the
possibility that the given gene expression may reach extreme
values, high or low. Such extreme values are argued in this report
to be the ‘‘flashpoints’’ of sporadic disease. In some types of
pathology (cancer, sporadic prionic disease) only a single
‘‘extreme’’ cell may be sufficient to cause systemic effect. In other
pathologies (Alzheimer’s disease, atherosclerosis, stroke, heart
attack) a critical weight of deregulated population has to be
reached. In all cases, increased variability in expression levels
would facilitate reaching of the critical ‘‘triggering’’ parameters,
thus its direct measurement may have diagnostic and prognostic
value. A combination of instabilities in regulation of expression of
several mechanistically important genes may exert effects compa-
rable to mutations. Currently, the classifiers of disease etiology and
prognosis utilize SNP, microarray, proteomic and metabolomic
data aligning particular pattern signatures with clinical correlates
[24,25]. A recent trend is to use peripheral blood samples for such
purposes [26,27]. Mostly, the current methods rely on point
mutations (RFLP markers, SNP, polymorphisms). In this report we
propose measuring cell-to-cell variations of gene expression in the
peripheral blood sample taken from a given individual.
Variability studies performed over single monocytes of a
peripheral blood sample from the given patient and covering
the most informative high-variability gene subset may bring an
additional dimension to genetic marker methodology. Thus,
variametric component should enhance genetic polymorphism
analysis regarding predisposition to chronic disease, diagnostics
of congenial disorders, longevity, personalized diet and
therapy. On the technical side, multiple expression levels in
single cells comprising a sample can be measured by the novel
methods of single cell arrays, phosphocytometry and cellomics
[28,29].
B. The expression variation study and its relation to the
progress of anti-cancer therapy
Our data facilitate understanding of limitations existing in
cancer therapy and also suggest novel therapeutic possibilities. For
example, we demonstrate (Figures 1, 3, 8) that pharmacological
targets display increased expression variability.
The effect is especially striking for tissue-specific anti-cancer
targets that are in the current focus of research relying on
differential expression (Figure 6).
We have conducted a genomic-scale differential expression
study. The latter comprised 40 pairs of normal versus cancer
Affymetrix array datasets, covering most of tissue environments in
a single computational space. The goal was to observe cancer-
specific hyper-expression absent in the entire panel of norm. The
initial hypothesis stated that such hyper-expression would be a
reliable basis for high quality target candidates. Preferably, such
hyper-expression should have been tissue-specific. Surprisingly,
we observed that such target candidates display the highest
variability in all categories studied in this report (Figure 3). Based
on this finding, situations are possible when personalized
expression profile of a target dramatically differs from the
population average profile. The genes over-expressed in cancer vs
norm at population level and used as selective targets may be
down-regulated at the level of an individual. Conversely, the
genes mediating the side effects can be over-expressed in normal
tissues and be silenced in a tumor. Such combinations of
expression parameters are very likely to cause failure of therapy.
In this case extreme cancer target variability would play against
the patient. However, opposite situations are possible, when the
therapeutic target is extremely over-expressed in tumor, while the
side effect determinants in the normal tissues are rudimental.
Such situations may lead to increased chance of success. The fact
that cancer expression is poorly regulated is trivial. However, the
fact that this ‘‘regulation defect’’ is especially concentrated in the
subset of genes, proposed for anti-cancer therapy is very
meaningful.
We show (based on reliability theory) that the survival
probability would be impacted by these fluctuation factors in the
most dramatic manner. Consequently, we emphasize personal-
ized target visualization approaches taking into account increased
target variability described in this report. Some genes – such as
metalloprotease MMP12 – display very favorable variation profile,
being almost uniformly over-expressed in cancer and almost
absent in norm. Conjugating visualizing and therapeutic moieties
to MMP12 ligands may be promising. Similar use of other MMP
ligands can be considered. Attachment of colloid gold nanopar-
ticles to such ligands would enable selective gold build-up in tumor
sites with subsequent enhancement of therapeutic X-ray absorp-
tion. The long-term cancer survival rate in the presence of such
gold nano-particles during a systemic radiotherapy comprises 86%
Figure 7. Functional analysis of gene categories displaying
opposing extremes of expression variability. Comparative results
of key-word searching of the most and least disease-related functional
categories. The 7500 functional categories produced by AMIGO
ontological classification were filtered resulting in ,3900 with non-
zero population. Multiple randomly drawn sets of genes (500-1000 in
size) served as negative control. The functional enrichment coefficients
(FENR) were computed in the AMIGO-represented negative control and
similarly treated disease-related datasets. The strings of FENR formed
random and disease-related sub-profiles in each functional category.
The sub-profiles were compared by T-test and p-values were sorted.
The functional categories with the least p-values (best 10% of rank,
p,10–11) were termed ‘‘most disease-related’’ (black bars). The
functional categories with the highest p-values (.0.9) were termed
‘‘least disease-related’’ (striped bars). Grey bars stand for the total
population of AMIGO-derived functions. The most and the least disease-
related groups of functional categories were searched using the
keyword combinations, such as ‘‘regulation’’, ‘‘positive regulation’’ and
‘‘negative regulation’’. The fractions of the functions responding to the
keyword combinations were computed and plotted.
doi:10.1371/journal.pone.0005921.g007
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due to local absorbance and scattering of X-ray energy on the
clusters of D-element atoms (gold in this case). In our differential
expression studies, some tumor types (glioma, melanoma, small
intestine cancer) displayed more tissue-specific over-expression
events, while many cancers did not. However, the MMP12
expression profile presented in this work was derived using lung
tissue data. This observation makes MMP-based approaches more
universal. For more detail see Supporting Materials, Text S1, pp
29–46.
The proposed therapy was described as an example of
approaches suggested by the results of our work. Currently,
significant investment in time and funds is consumed by the study
of molecular signaling associated with cancer targets. At the same
time, especially high expression variation associated with such
targets questions uniformity of their presence in malignant clonal
population and the significance of using blockers against such
targets. However, using over-expressing clones as attachment sites
for selective delivery of radioactivity appears to be bypassing these
difficulties. Absorption and scattering of radiation by such
attachment sites would create ‘‘killing zones’’, encompassing the
malignant clones that insufficiently express a particular target and
do not depend on it for survival.
C. The expression variation study and its impact upon
identification of successful pharmacological targets
The high cost of new therapeutics against chronic disease drains
the resources of society by forcing higher health care spending and
by detracting from the vital task of anti-infective development. In
the context of SARS outbreak and our new knowledge of
pandemic flu genesis it becomes imperative to produce compu-
tational signatures: of the anti-infective targets, of the successful
targets against chronic disease, and of the ligands capable of being
viable leads. Apparently, lagging in these technologies opens
vulnerabilities at global scale, considering the issues of microbial
drug resistance, bioengineering and bio-terror.
Based on the findings of this report, we rationalized and
advanced the criteria of target prioritization, previously published
in [31]. In the latter publication we show that the future
therapeutic success of a prospective target can be predicted a-
priori in large integrated datasets, based on the gene’s expression
behavior. In the current report we attempted to rationalize this
link.
Ontological analysis reveals that the genes of high variability
class may require more sophisticated orchestration of their
functions (P4.13-P4.14). At the same time low variability genes
(enzymes, cytoskeleton components, ribosomes) appear to be
Figure 8. Analysis of pharmacological target efficiency in the context of expression variability. A. Resolution of successful anti-cancer
targets (black squares), developing anti-cancer targets (black triangles), non-cancer disease targets (black diamonds) as a function of a combined
variation score. The score is obtained by integrating MAX/MIN, coefficient of variation, kurtosis and differential expression criteria of expression
variation. The genes were ranked by the combined score in the descending order and at each fraction of the rank the fractions of random genes and
the corresponding targets were computed. The results are presented as ROC curves. B. Resolution of successful antibiotic targets, developing targets
and random genes as a function of variation. The ROC curve presents ‘‘false positives’’ – random population (black diamonds) ranked in ascending
order by MAX/MIN of transcription profile, 0 corresponding to the minimal MAX/MIN, 1 corresponding to the maximal. ‘‘True positives’’ refer to the
targets of successful antibacterial drugs (black triangles) and developing antibiotic targets (black squares). The integrated numbers of true and false
positives, reached at a particular fraction of the ranking were counted, converted into fractions and plotted vs. fraction of the ranking. C. Distribution
of successful antibiotic targets (black bars), developing antibiotic targets (striped bars) and random genes (grey bars) as a function of evolutional
conservation. The conservation is defined by a fraction of organisms in a phylogenetic profile expressing the orthologs of the given target. The profile
comprises 26 bacterial species according to Cluster Of Ortholog Groups database (COG at http://www.ncbi.nlm.nih.gov/COG/, 2004 edition).
doi:10.1371/journal.pone.0005921.g008
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in agreement with external variability model published in [4]. The
functions that require more coordination are statistically more
error-prone and thus the link between variability and disease
can be rationalized at mechanistic level. Namely, the most of
variations occur in the expression levels of genes carrying out
sophisticated regulatory functions.
As an example, genes expressed only in a particular tissue
lineage display more variable expression than the genes expressed
systemically (compare Figure 1 and 3). Tissue-specific expression
imposes an additional level of control and leads to increased
sophistication of transcription regulation. Disease-related gene
classes are 4-fold enriched in regulatory functional categories vs.
random genes (Figure 7). As compared to random genes,
regulators are subject to more sophisticated orchestration due to
downstream systemic leverage. The regulators are sought as
pharmacological targets, if other criteria are met. Therefore, high
variability of a gene’s expression may point to the complexity of
regulation that is indicative of its signal or adaptive role.
At the same time, broad variations in the levels of the most
upstream regulators are unlikely to be compatible with life -
therefore distribution of variation across the tiers of significance
should be optimized, by maximized population survival. One can
observe these principles following the trends discovered in target
success analysis (Figures 8.A–C). Indeed, the goal of non-cancer
therapy is to normalize the cell population of interest. The effects
of such therapy are typically not cytotoxic and thus may be
mediated by signal transducers carrying the maximal systemic
impact. Such transducers appear to be provided with stricter
expression stability controls, and such controls may override the
putative increased variability of signal networks. As a result,
average variation of successful targets against non-cancer disease
(Figure 8.A) is below the one observed for the candidate genes
(Figure 4), although also above the random level.
The goal of anti-cancer therapy is to eliminate the cell
population of interest and such therapies – in final reckoning –
are cytotoxic. Using the uppermost significance tier of signal
transducers for such purposes would endanger normal cells. The
signal transducers of lower significance tiers may be more
important for tumor than norm and a therapeutic window opens.
However, at this level of significance the expression stability
controls are less strict and the inherent increased expression
variability of signal transducers prevails in this tier. As a result, the
expression variability of successful anti-cancer targets exceeds the
one for candidate genes (Figure 1 and 4). This hypothesis suggests
that anti-cancer ‘‘targeted’’ therapy displays fundamental limita-
tion, since the best anti-cancer targets are located in the secondary
tier of significance, not in the primary one.
The goal of antibiotic therapy is to eliminate the bacterial
population too. Due to wide evolutional (and structural)
divergence, there is a ‘‘luxury’’ of inhibiting the most significant
tier of functional elements in the prokaryotic cell with minimal risk
to normal human tissues. Correspondingly, the prokaryotic targets
display increased evolutional conservation and decreased expres-
sion variability as compared to random genes (Figure 8.B, C).
Instructively, several penicillin-binding proteins exist in E. coli, but
only dacB (the actual penicillin target) displays low expression
variation. The target candidates in development appear to behave
similar to random population in this regard and appear to be less
evolutionally conserved (Figure 8. B and C ). Our research
comprises integrative, multi-facet analysis, and recent years show
the progress in this field [32,33]. Thus, our study identifies
additional criteria of optimized antibiotic therapy design and
prepares ground for a cost-efficient and rapid development of such
a therapy, see Supporting data, Text S1, p 23–24. In this report we
did not set a goal of employing all possible classification features
and achieving maximal resolution. Rather, it was a demonstration
that successful targets in each category display specific trends. In a
broader context, this comparative study of therapeutic target
variability provided important insight in the limitations of anti-
cancer targeted therapy and in the link between disease on-set and
variation.
The limited volume of a journal publication does not allow
answering all numerous questions raised by our findings. First, there
is a paradox: according to Figures 1–7, expression variation does
parallel chronicdisease.Onthe otherhand,according to theanalysis
ofFigures8.A–Cananti-variation mechanismappearsto protect the
most significant tier of biological functions. How a fledging disease
overrides such a mechanism of expression stability control?
The answers to this and other questions are provided in
Supporting material, Text S1, pp 7–28.
Supporting Data
The Supporting data are available online at the link: www.
mayburd.com
The primary data and processing files in Excel format are
designated by letter P. They comprise initial downloads (the
folders P1), datasets covering tissue environments in norm (P2
folder ‘‘Norm alone’’) and in cancer (P2 folder ‘‘Cancer alone’’).
The file P2.4 comprises integrated panel of differential expression.
The supporting materials further comprise assembled panel of
variability (folders P3.1, P3.2), alignment of expression parameters
(including variability) with target mechanistic data (P3.3, P3.4), the
files P4 supports ontological analysis. Each Excel file is also
described and annotated in its top left part.
Supporting material in Word format is referred to by Text S1 in
the text and contains all details not included in the up-front
manuscript as well as description of the supporting data.
Methods
Datasets and Databases
Large-scale microarray profiling of disease and norm as well as
smaller scale datasets were downloaded from Global Expression
Omnibus (GEO) platform at NCBI [34]. In particular, Expression
Project for Oncology (expO) was downloaded as record GSE2109
at GEO database [35]. The data for normal expression (Human
Body Index project) were downloaded as GSE7307 and GSE3526
[34]. Multiple smaller projects describing either cancer expression
alone or in comparative norm vs. cancer setting were extracted. In
this report U133 Plus 2.0 Affymetrix Array (Santa Clara, CA) was
used for all major measurements (see GPL570 platform at GEO
for more detail and annotation). Prokaryotic data were derived in
Affymetrix GeneChip E. coli Antisense Genome Array platform
(GPL199, dataset GDS1827).
Experimental noise reduction
Aggregating of multiple microarray experiments by diverse
authors poses unique challenges due to a significant component of
technical noise, overlaid with biological variability. Several steps
were taken to maximize the benefits of dataset aggregation in
terms of signal-to-noise ratio.
a) Selection of high quality dataset components of the
integrated panel. Low quality datasets were excluded from the
analysis if they presented low levels of signal (that may indicate
insufficient hybridization to the probes), evidence of missing genes,
imputed data, datasets that are too small (,4 samples).
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project component of the panel. The results pertaining to N
samples identically processed were defined as ‘‘project’’. The
averages for each sample were computed among 54670 probe-set
readings comprising all genes included in U133 Plus 2.0
microarray by Affymetrix (Santa Clara, CA). Each individual
gene expression value in the column of 54670 probe-sets was
normalized by that average. Variability was measured as a ratio of
maximal and minimal outliers in the profile of N normalized
samples obtained under identical conditions and representing the
same tissue lineage. The ratios (MAX/MIN) were combined in a
large-scale panel of 80 values per each gene, each value
representing a dataset (project) component of a panel
(Supporting materials, folder P3.1.1; Text S1, tables 1–2, page 8).
c) Minimization of disproportionate contributions in the
integrating panel by ‘‘noisy’’ projects. The MAX/MIN
value refers to a project of N samples. MAX/MIN ratios were
converted into Z scores:
Z~ XI{XM ðÞ =sM ð3Þ
Where XI is the given MAX/MIN value for the i-th probe-set; XM
is the average MAX/MIN among 54675 values, sM is the
standard deviation of MAX/MIN among 54675 values (probe-set
population of a microarray). Xi,X m and sM all refer to ranked
values of MAX/MIN. This procedure allows integrating
experiments where levels of variability were very different and
thus prevents skewing of the resulting panel data in favor of
accidentally higher variability values (Supporting materials, folder
P3.1.3; Text S1, table 3, page 10)
d) Maximization of signal-to-noise ratio by exemption of
noise-rich subpopulation. The Z scores were plotted using Q-
Q plotting procedure against a theoretical model based on normal
distribution [37]. The empirical relative frequencies of high Z
score values were compared with the ideal probability values based
on the assumption of normal distribution. The concordant regions
of Z scores were discarded, since signal-to-noise ratio in such
regions is low. The discordant regions of Z scores (on positive side,
Z.2) were preserved. Such regions contribute comparatively
higher signal-to-noise ratio. The Z scores in the range .2 were
summed up and averaged across the panel of 80 expression
datasets (P3.1.4; P3.15).
e) Minimization of technical noise by comparing large
groups of genes. All compared groups and subgroups
comprised .150 genes. Finer sub-divisions were avoided.
f) Confirmation of trends in related groups. All trends
established in this research were confirmed in multiple groups, for
example the difference between FDA-approved anti-cancer targets
and random genes was supported by the difference between
proposed anti-cancer targets and random genes.
Validation of variability panel data
To exclude a fortuitous panel composition as a source of results,
bootstrapping procedure was applied to produce 8 random sub-
panels (P3.3). In each sub-panel variability was computed. The
procedure produced two sets of 8 values for FDA-approved anti-
cancer target variability and random gene variability. The
reproducibility in the sets of bootstrap-generated values was
assessed by plotting confidence intervals at a =0.05.
Alternative metrics of variability
The metrics comprised: a) coefficient of variation (CV) defined
as the ratio of variance in the profile to the average of the profile b)
kurtosis (measure of deviation from normal distribution in the
profile)
Expression and differential expression consistency
(DEXCON)
To compute gene expression levels, each dataset component of
the integrating panel was normalized as described above (each
sample divided by array average intensity). The paired panels of
31 matching cancer and normal datasets produced a profile of
differential expression values for each probe-set. Those values that
exceeded 3-fold up-regulation were preserved and the rest were
replaced by zeros, to maximize signal-to-noise ratio. The resulting
indexes of consistent up-regulation were computed for the panel of
data (P2.3, P2.4).
Metrics of tissue-specific expression
Microarray data were organized in gene expression panels, each
composed of M experiments, each experiment comprising N
samples. The expression data were normalized as described above
and averaged for each experiment. Thus Normal Expression panel
and Cancer Expression panel contained M1 and M2 averaged
values each. Several criteria of tissue-specific expression were
defined. The MAXC is the maximal expression level in the panel
of M2 normalized cancer environments; MAXN is the maximal
expression level among M1 normalized disease-free tissue
environments, AV is the average level in the norm (average of
M1 experiments) and VULNERABLES is the average level
measured in the sub-panel of normal tissues most often suffering
from side effects of therapy. Cancer expression was characterized
by ratios of MAXC/MAXN; MAXC/AV; MAXC/VULNER-
ABLES. Simultaneously high ratios indicate a potentially cancer-
specific expression level, only minimally expressed in norm. Such
profiles were assumed to indicate potential target candidates,
specific for a particular cancer lineage and minimally expressed in
normal tissues (P5, RIT1).
Definition of disease-related genes and alignment with
expression parameters
The disease-association status follows key-word querying of the
database ‘‘Genes’’ at NCBI [38]. The database is filled by text-
mining of biomedical literature and comprises all grades of
association. No prioritization within the gene list was performed.
To produce a query, the most common name of a disease was
used, for example ‘‘diabetes’’, ‘‘atherosclerosis’’, ‘‘aging’’, etc. The
search results were exported and gene aliases were aligned with the
variability, gene expression and DEXCON (P3.2).
Quantitative ontological analysis
The genes comprising the datasets of study (,54675 probe-sets)
were ranked based on variability and the highest and lowest
groups by rank were selected, ,500 probe-sets in each. The classes
were compared by GO-MINER methodology [39,40]. The
statistically representative random group (,30000 genes, the
entire array population) was selected to produce the ‘‘total’’
required by GO-MINER algorithm. The functional enrichment
coefficients were computed as ratios:
FENR~ Ci=Pi ðÞ Ct=Pt ðÞ ð 4Þ
Where FENR is functional enrichment coefficient; Ci is population
in the category of interest generated by a studied sub-set of genes;
Pi is population in the studied sub-set of genes; Ct is population in
the same category of interest generated by a total sub-set of genes;
Disease Origin
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and low variability groups were compared. The FENR were also
computed for individual diseases and FDA-approved target
datasets. The values of FENR were organized in profiles, each
functional category corresponding to N values for major human
diseases.
To rule out the possibility that any given FENR arises
accidentally and does not have a biological meaning, 12 randomly
selected sets of genes of the size 500–1000 were processed by GO-
MINER, establishing a negative control. These values of FENR
were also organized in profiles per each functional GO-MINER
category. The sub-profiles for random genes and diseases were
compared using T-test and the resulting p-values were ranked.
The most disease-associated functional categories were defined by
difference between negative control FENR profiles vs. disease-
related FENR profiles (p,10
211). With the T-test p-values being
sorted in ascending order, this category forms the top 10% of a
rank.
To produce the minimal p-value (the strongest T-test), the
disease-related FENR profile has to display minimal scattering,
thus the highest ranking belonged to the functional categories
corresponding to the most generic features of chronic disease,
equally displayed by all pathologies and absent in the negative
random control. For illustration see P4, file ‘‘Analysis’’ in SM. The
top-ranking and lowest-ranking functional categories, as well as the
total list were text-mined with the keywords of interest and the
data were plotted.
Supporting Information
Text S1 Supporing text and in-depth presentation
Found at: doi:10.1371/journal.pone.0005921.s001 (0.61 MB
DOC)
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